Sleep
Narcolepsy
search
Narcolepsy
, Gelineau Syndrome, Paroxysmal Sleep, Narcoleptic Syndrome
Epidemiology
Prevalence
: 40 per 100,000 (0.02 to 0.18% of adults)
Men and women affected equally
Onset in teens and young adults, ages 10 to 20 years old (rarely has onset after age 50 years)
Pathophysiology
Excessive
Sleepiness
Abnormal
REM Sleep
Causes
Idiopathic
Hereditary related to DR-2
Secondary causes
Head Trauma
Encephalopathy
Brain Tumor
Cerebrovascular insufficiency
Symptoms
Classic Tetrad
Recurrent irresistible
Daytime Sleepiness
Occurs unexpectedly and at inappropriate times
Cataplexy
(25-30% of patients with Narcolepsy)
Sudden decrease or loss of voluntary
Muscle
tone following emotional trigger (e.g. laughing, surprise)
Episodes last seconds to minutes
Localized hypotonia (e.g. jaw drop, head nod, knee sag)
Gene
ralized hypotonia (full collapse onto floor)
Sleep
Hallucination
s
Hypnagogic
Hallucination
s (on falling asleep)
Hypnopompic
Hallucination
s (on awakening)
Sleep Paralysis
Transient, generalized inability to move or speak during sleep-wake transition
Differential Diagnosis
See
Hypersomnolence
Sleep Apnea
Other Primary
Hypersomnia
(uncommon)
Idiopathic
Hypersomnia
Menstrual
Hypersomnia
Kleine-Levin Syndrome (rare syndrome of male teens)
Evaluation
See
Hypersomnolence
Diagnosis
Sleep Study
(all patients)
Sleep
log or
Actigraphy
for 2 weeks
Multiple
Sleep Latency
Test (daytime nap test)
Polysomnogram
performed for monitoring
At least 2 naps with early onset
REM Sleep
(Rapid transition to REM)
Shortened REM latency (<8 minutes compared with 15 minutes for unaffected patients)
Management
Gene
ral Measures
Schedule naps
Keep a consistent sleep schedule
Practice
Sleep Hygiene
Plan
Caffeine
use prior to times of needed wakefulness
Management
Standard Medications
See
Hypersomnia
First-Line Stimulants for Excessive
Daytime Sleepiness
Modafinil
(
Provigil
)
Best safety profile and lowest abuse potential of all stimulant agents
Armodafinil (Nuvigil, generic)
Solriamfetol (Sunosi, expensive)
Other stimulants (risk of dependence) for Excessive
Daytime Sleepiness
Methylphenidate
(
Ritalin
)
Dextroamphetamine
(
Dexedrine
)
Symptomatic management of
Cataplexy
,
Sleep Paralysis
or hypnagogic
Hallucination
s
SNRI
(e.g.
Venlafaxine
) and
SSRI
agents (e.g.
Fluoxetine
) suppress
REM Sleep
Clomipramine
(
Anafranil
)
Combined stimulant and
Cataplexy
agents
Gamma hydroxybutyric acid or
Sodium
oxybate (Xyrem)
Given twice nightly
Pitolisant (Wakix)
Fewer adverse effects as
Sodium
oxybate with similar efficacy
Xu (2019) Sleep Med 64:62-70 [PubMed]
References
Billiard (2008) Neuropsychiatr Dis Treat 4(3):557-66 [PubMed]
Holder (2022) Am Fam Physician 105(4): 397-405 [PubMed]
Pagel (2009) Am Fam Physician 79(5): 391-6 [PubMed]
Thorpy (2006) CNS Drugs 20(1): 43-50 [PubMed]
Ramar (2013) Am Fam Physician 88(4): 231-8 [PubMed]
Type your search phrase here